RecruitingNot ApplicableNCT07677787

DLL3-Targeted PET/CT in Small Cell Lung Cancer

Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

20 participants

Start Date

May 9, 2026

Study Type

INTERVENTIONAL

Conditions

PET/CT Small Cell Lung Cancer ( SCLC )DLL3-targeted PET/CT Delta-like Protein 3

Summary

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT for people with dll3-targeted pet/ct, delta-like protein 3, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTconventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT

Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.

Locations(1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07677787

Related Trials

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

NCT0722699973 locations

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

NCT07472517242 locations

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT0565268615 locations

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT0346097783 locations

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

NCT073586761 location